Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Western Union (WU) Admits Anti-Money Laundering and Consumer Fraud Violations, Forfeits $586M in Settlement
- Pulmatrix (PULM) Halted on LUDP, Shares Up 105%
- Epizyme (EPZM) Received Written Response from FDA Allowing Enrollment of FL Patients in Phase 2 Tazemetostat Trial
Create E-mail Alert Related CategoriesFDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!